Tools   Select Another Resource Report Type

http://www.yale.edu/herzongroup/Herzon_Lab/Home.html

My laboratory has created a family of natural product-inspired anticancer agents. We have evaluated our compounds at the Yale Center for Chemical Genomics, and they are exhibiting IC50 values in the low nM range against K562, HeLa, LnCAP, and HCT-116 lines. Their mechanism of action is unknown, although the natural products have been shown to cleave DNA. An evaluation of the natural products at the NCI has shown that they have a toxicity profile that is distinct from other known DNA damaging agents. We can readily access gram-quantities of these agents for further studies. We are looking for researchers who might find these compounds useful in medicinal applications, for example, for treatment of a specific cancer. We are capable of synthesizing new analogs, such as those incorporating a specific recognition or targeting element, and would be excited to pursue this avenue of research.

Proper citation: Herzon Lab (RRID:SCR_008850) Copy   

•   Source: SciCrunch Registry

http://omrf.org/

A biomedical research institute that aims to understand and develop more effective treatments for human disease, focusing on critical research areas such as heart disease, cancer, lupus and Alzheimer's disease.

Proper citation: Oklahoma Medical Research Foundation (RRID:SCR_005287) Copy   

•   Source: SciCrunch Registry

https://www.urmc.rochester.edu/neurosurgery/specialties/neurooncology.aspx

Collaborative neuro-oncology research program with a tissue repository (tumor bank) containing a wide range of clinical specimens, which they make available to researchers in order to study the effects of new drugs on a large number and wide range of tumor specimens. They provide highly coordinated, complex care in neurosurgery, radiation oncology, medical oncology, and neurology to patients afflicted with tumors of the brain and spine by combining the newest technologies and treatments available anywhere in the world. The program is formed from a multidisciplinary group with a goal of helping patients navigate the complex issues surrounding brain and spinal cancer care. The researchers are working to increase the number of targets that could be considered for anti-angiogenesis therapy. Many of their studies focus on the blood vessel cells (endothelial cells) themselves, which, unlike tumor cells, rarely mutate and so might be less likely to become resistant to therapy and are also more easily reached through the bloodstream. Their researchers are also attempting to better understand the changes in the blood-brain barrier (BBB) that are associated with fluid accumulation and brain swelling (edema) in neuro-oncology patients. Normal brain tissue is shielded from the rest of the body by the BBB. This barrier is composed of very tight blood vessels that prevent most substances from entering the brain. Brain tumors have a leaky BBB ����?? this feature can be used to identify tumors on MRI scans. They have identified specific molecules that appear to be associated with the leaky, abnormal vessels while the normal blood vessels with intact BBB produce these molecules at very low levels or not at all. Inhibiting the function of these molecules may help control or prevent disruption of the BBB and limit cerebral edema in brain tumor patients, as well as patients suffering from stroke or traumatic brain injury.

Proper citation: University of Rochester Program for Brain Tumors and Spinal Tumors (RRID:SCR_005343) Copy   

•   Source: SciCrunch Registry

http://cancer.ucsf.edu/research/cores/biostatistics

The Biostatistics Core provides statistical support for cancer-related research at UCSF, focusing particulary on applications in clinical trials and population studies. The Computational Biology Core supports applications to genomics, genetics and molecular biology. Core faculty have expertise in study design, protocol and proposal development and review, data analysis, and publication of results. Support for Cancer Center investigators participating in established Site Committees is typically handled by the faculty member assigned to that committee. Other requests can be directed to the consulting service request page maintained by the UCSF Clinical & Translational Science Institute (CTSI). These requests will then be assigned to a Core faculty member. Basic consulting services are generally provided free of charge to Cancer Center Members. Members requiring frequent assistance are encouraged to provide regular salary support to a Core statistician when possible to support more extensive requests and for long-term projects. Services: * Study Design * Guidance on Study Conduct * Data Analysis and Reporting of Study Results * Teaching resources

Proper citation: UCSF Helen Diller Family Comprehensive Cancer Center Biostatistics Core (RRID:SCR_005701) Copy   

•   Source: SciCrunch Registry

http://www.terryfox.org/

The Terry Fox Foundation is responsible for supporting close to $20 million in discovery based research each year in Canada - all monies raised outside Canada must be distributed to (a) an institute approved by the Foundation and its advisors or (b) remitted to Canada. The Terry Fox Research Institute (TFRI) is a recipient of TFF funding for translational research. TFRI is an exciting new initiative whose goal is to translate rapidly today''s best science into better cancer treatment and diagnosis for all Canadians. The Institute will bring scientists and clinicians together across the country into a functionally integrated, geographically dispersed Institute with nodes in several provinces. Terry Fox was diagnosed with osteogenic sarcoma (bone cancer) in his right leg in 1977 and had his leg amputated 15 cm (six inches) above the knee. While in hospital, Terry was so overcome by the suffering of other cancer patients that he decided to run across Canada to raise money for cancer research. He called his journey the Marathon of Hope. Terry''s Marathon of Hope took place in 1980 with the simple objective of informing Canadians of the importance of finding a cure for cancer. With fierce determination, he ran an average of 42 kilometres (26 miles) every day for 143 days. Terry was forced to end his run on September 1, 1980 when the cancer spread to his lungs. By February 1, 1981, Terry''s dream of raising $1 for every Canadian was realized - the Terry Fox Marathon of Hope fund totaled $24.17 million. Terry died in June 1981. On May 26, 1988, The Terry Fox Run became a Trust, independent from the Canadian Cancer Society, and received tax-exempt charitable registration as a public foundation. In addition to our signature and long-standing National Terry Fox Run Day in September of each year, The Terry Fox Foundation is proud to include in its events portfolio The National School Run Day. The Foundation recognizes the duality of its mandate. Not only does it raise money for research, but it also continues to share the story of Terry Fox. The Terry Fox Foundation strives to maintain the heroic effort and integrity that Terry embodied. It is a grassroots organization that does not allow the Terry Fox name or likeness to be commercialized or conjoined with other worthy causes. To date, over $600 million has been raised worldwide for cancer research in Terry''s name.

Proper citation: Terry Fox Foundation (RRID:SCR_005873) Copy   

•   Source: SciCrunch Registry

http://ucsd.researchaccelerator.org/

Software platform that allows researchers to easily collaborate on research and share reagents, antibodies, cell lines and more. It is designed to increase scientific collaboration across disciplines and geographical boundaries. Among the institutions now using the platform include Yale University, U of Pennsylvania, U of Chicago, Washington U, Cambridge University, University College London. The platform is licensed to select institutions. ResearchAccelerator.org allows researchers to form targeted, data driven collaborations. Researchers can search for data based on gene, disease and pathway, and they can post data which would otherwise be orphaned. The resulting collaborations, which are likely to be transdisciplinary, can greatly amplify impact and research productivity.

Proper citation: Research Accelerator (RRID:SCR_006051) Copy   

•   Source: SciCrunch Registry

http://www.actrec.gov.in/

The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) is the new state-of-the-art R&D satellite of the Tata Memorial Centre (TMC), which also includes under its umbrella the Tata Memorial Hospital (TMH), the largest cancer hospital in Asia. ACTREC has the mandate to function as a national centre for treatment, research and education in cancer. TMC is an autonomous grant-in-aid institution of the Department of Atomic Energy (DAE), Government of India. It is registered under the Societies Registration Act (1860) and the Bombay Public Trust Act (1950). Its Governing Council is headed by the Chairman, Atomic Energy Commission, Government of India. ACTREC comprises of 2 arms - one for basic research and another for clinical research. The basic research building was inaugurated in March 2002 at the new site of ACTREC in Kharghar, Navi Mumbai. In August 2002, the Cancer Research Institute (CRI) shifted in toto from its Parel campus in Mumbai to serve as the basic research arm of ACTREC. The clinical research arm of ACTREC comprising of the Clinical Research Centre (CRC) has become functional from March 2005. ACTREC also has a 50-bed hospital fully equipped with state-of-the-art diagnostic and therapeutic facilities. Research investigations at CRI currently focus on molecular mechanisms responsible for causation of major human cancers relevant to India. It is envisaged that in the future, ACTREC will play a greater role in drug development and emerging therapies for treatment and prevention of cancer.

Proper citation: ACTREC - Advanced Centre for Treatment Research and Education in Cancer (RRID:SCR_006021) Copy   

•   Source: SciCrunch Registry

http://www.wikicancer.org/

A place where people connected to cancer can share real-life experiences -- fears, insights, stories, and advice. Adding perspectives is easy, and every contribution builds the site into a more valuable and unique community resource. Content, resources, and support on wikiCancer: * Just been diagnosed with cancer? * Living with cancer * For cancer survivors * How to support someone with cancer * Connect with other cancer patients, survivors, family and caregivers

Proper citation: wikiCancer (RRID:SCR_001824) Copy   

•   Source: SciCrunch Registry

http://thelongevityfoundation.org/

Funding resource that supports research into A-T (Ataxia Telangiectasia) and other debilitating, degenerative diseases plaguing human kind, including cancer and neuro-degeneration associated with auto-immunity and aging. Researchers share their findings and collaborate with each other. The research must lead to practical, near-term treatments and cures to receive funds. The researchers have found treatments and cures that are the first of their kind in the world. Over $850,000 in direct research grants have been made. These grants have leveraged over $9 million in research resources contributed by partner institutions. We pay the research institutions for direct costs only. We pay no administrative, indirect, or overhead costs.

Proper citation: Longevity Foundation (RRID:SCR_006338) Copy   

•   Source: SciCrunch Registry

http://www.uni-koeln.de/med-fak/cgars/

Software package to dissect random from non-random patterns in copy number data and thereby to assess significantly enriched somatic copy number aberrations (SCNA) across a set of tumor specimens or cell lines.

Proper citation: CGARS (RRID:SCR_006404) Copy   

•   Source: SciCrunch Registry

http://bioinf.wehi.edu.au/socrates/

Software for detecting genomic rearrangements in tumors that utilizes only split-read data. It features single nucleotide resolution, high sensitivity, and high specificity in simulated data. It takes advantage of parallelism for efficient use of resources.

Proper citation: Socrates (RRID:SCR_006411) Copy   

•   Source: SciCrunch Registry

http://bioinformatics.oxfordjournals.org/content/early/2014/01/02/bioinformatics.btt759.abstract?sid=e62f3c2b-26dc-428b-ba24-99e92a277d77

Statistical software to estimate tumor purity, ploidy and absolute copy numbers from next generation sequencing data.

Proper citation: AbsCN-seq (RRID:SCR_006409) Copy   

•   Source: SciCrunch Registry

http://lincs.hms.harvard.edu/db/

Database that contains all publicly available HMS LINCS datasets and information for each dataset about experimental reagents and experimental and data analysis protocols. Experimental reagents include small molecule perturbagens, cells, antibodies, and proteins.

Proper citation: HMS LINCS Database (RRID:SCR_006454) Copy   

•   Source: SciCrunch Registry

http://cdmrp.army.mil/

Fund the best research to eradicate diseases and support the warfighter to benefit the American Public. They promote innovative research, recognizing untapped opportunities, creating partnerships, and guarding the public trust. Research Program topics include: * Amyotrophic Lateral Sclerosis * Autism * Bone Marrow Failure * Breast Cancer * Defense Medical Research and Development Program * Duchenne Muscular Dystrophy * Gulf War Illness * Lung Cancer * Multiple Sclerosis * Neurofibromatosis * Ovarian Cancer * Peer Reviewed Cancer * Peer Reviewed Medical * Peer Reviewed Orthopaedic * Prostate Cancer * Psychological Health / Traumatic Brain Injury * Spinal Cord Injury * Tuberous Sclerosis Complex

Proper citation: Congressionally Directed Medical Research Program (RRID:SCR_006456) Copy   

•   Source: SciCrunch Registry

http://wiki.chasmsoftware.org/index.php/Main_Page

CHASM is a method that predicts the functional significance of somatic missense mutations observed in the genomes of cancer cells, allowing mutations to be prioritized in subsequent functional studies, based on the probability that they give the cells a selective survival advantage. SNV-Box is a database of pre-computed features of all possible amino acid substitutions at every position of the annotated human exome. Users can rapidly retrieve features for a given protein amino acid substitution for use in machine learning.

Proper citation: CHASM/SNV-Box (RRID:SCR_006445) Copy   

•   Source: SciCrunch Registry

http://dgidb.genome.wustl.edu/

A database of drug-gene relationships that provides drug-gene interactions and potential druggability data given list of genes. There are about 15 data sources that are being aggregated by DGIdb, with update date and these data sources are listed on this page: http://dgidb.genome.wustl.edu/sources, THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: DGIdb (RRID:SCR_006608) Copy   

•   Source: SciCrunch Registry

http://p53.fr

The UMD TP53 Mutation Database is a novel web site exclusively dedicated to mutant TP53. The following datasets, analytical tools and software are available. * The TP53 UMD mutation database in human cancer (2012 release). This novel release (35,000 mutations, 3,600 publications) has been highly curated using an original and novel statistical procedure (See Edlung et al. PNAS 2012). * TP53MUTLOAD (MUTant Loss Of Activity Database), a novel database dedicated to detailed analysis of the properties of each TP53 mutant, ranging from transactivation to cell growth properties, change of conformation, localization or various gains of functions. The database contains more than 110,000 different entries. * TP53 Mut assessor, a novel stand-alone software available for both Windows and Mac users. Check your favorite TP53 mutants and get an instant identity card. Very useful to analyze any newly discovered TP53 mutants, as the software checks for every possible TP53 mutation. * MUT-TP53 2.0, an accurate and powerful tool that automatically manages p53 mutations and generate tables ready for publication, decreasing the risk of typing errors. MUT-TP53 2.0 also provides specific information for each TP53 mutation, allowing the user to assess the quality of the data. Up to 500 TP53 mutations can be managed simultaneously.

Proper citation: UMD p53 Mutation Database (RRID:SCR_006720) Copy   

•   Source: SciCrunch Registry

http://www.proteinatlas.org/

Open access resource for human proteins. Used to search for specific genes or proteins or explore different resources, each focusing on particular aspect of the genome-wide analysis of the human proteins: Tissue, Brain, Single Cell, Subcellular, Cancer, Blood, Cell line, Structure and Interaction. Swedish-based program to map all human proteins in cells, tissues, and organs using integration of various omics technologies, including antibody-based imaging, mass spectrometry-based proteomics, transcriptomics, and systems biology. All the data in the knowledge resource is open access to allow scientists both in academia and industry to freely access the data for exploration of the human proteome.

Proper citation: The Human Protein Atlas (RRID:SCR_006710) Copy   

•   Source: SciCrunch Registry

http://www.thesgc.org/

Charity registered in United Kingdom whose mission is to accelerate research in new areas of human biology and drug discovery.Not for profit, public-private partnership that carries out basic science of relevance to drug discovery whose core mandate is to determine 3D structures on large scale and cost effectively targeting human proteins of biomedical importance and proteins from human parasites that represent potential drug targets.

Proper citation: Structural Genomics Consortium (RRID:SCR_003890) Copy   

•   Source: SciCrunch Registry

http://www.hybrigenics.com/

A bio-pharmaceutical company with a focus on research and development of new targets & therapies against proliferative diseases. Its current development program is based on inecalcitol, a vitamin D receptor agonist being studied in three potential indications: * alone in chronic lymphocytic leukaemia * in combination with imatinib in chronic myeloid leukaemia * in prostate cancer, for use with current standards of care Hybrigenics'' research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in the recycling of onco-proteins and the utility of proprietary patented DUB inhibitors against various cancer indications. Hybrigenics Services, a Hybrigenics subsidiary, markets very specialized scientific services to researchers in all areas of life sciences who want to identify, validate and inhibit protein interactions in animal, plant or microbiological cells.

Proper citation: Hybrigenics (RRID:SCR_003822) Copy   

•   Source: SciCrunch Registry